Citations

Mayo Clinic

Showing 10 of 108551 citations.

Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
Donev, Kliment , Sundararajan, Vanitha, Chambers, Meagan , Abdullaev, Zied , Quezado, Martha , Cimino, Patrick J. , Valério, Ediel , Castro, João Víctor Alves de , Wolff, Beatriz Martins , Kulikowski, Leslie Domenici , Aldape, Kenneth , Ida, Cristiane M. , Johnson, Derek, Ida, Cristiane M , Cimino, Patrick J , Johnson, Derek R. , Balan, Jagadheshwar , Paulson, Vera , Scherpelz, Kathryn P. , Pratt, Drew , Carraro, Dirce Maria , Torrezan, Giovana Tardin , Costa, Felipe D’Almeida

Journal of Neuropathology & Experimental Neurology | February 9, 2024 | Volume: 83 | Issue: 5 | Pages: 357-364

10.1093/jnen/nlae018 | PMID 38447592 Get It

Abstract Diffuse midline glioma, H3 K27-altered (DMG-H3 K27) is an aggressive group of diffuse gliomas that predominantly occurs in pediatric patients, involves midline structures, and displays loss of H3 p.K28me3 (K27me3) expression by immunohistochemistry and characteristic genetic/epigenetic profile. Rare examples of a diffuse glioma with an H3 p.K28M (K27M) mutation and without involvement of the midline structures, so-called “diffuse hemispheric glioma with H3 p.K28M (K27M) mutation” (DHG-H3 K27), have been reported. Herein, we describe 2 additional cases of radiologically confirmed DHG-H3 K27 and summarize previously reported cases. We performed histological, immunohistochemical, molecular, and DNA methylation analysis and provided clinical follow-up in both cases. Overall, DHG-H3 K27 is an unusual group of diffuse gliomas that shows similar clinical, histopathological, genomic, and epigenetic features to DMG-H3 K27 as well as enrichment for activating alterations in MAPK pathway genes. These findings suggest that DHG-H3 K27 is closely related to DMG-H3 K27 and may represent an unusual presentation of DMG-H3 K27 without apparent midline involvement and with frequent MAPK pathway activation. Detailed reports of additional cases with clinical follow-up will be important to expand our understanding of this unusual group of diffuse gliomas and to better define the clinical outcome and how to classify DHG-H3 K27.
Exercise testing unmasks exaggerated blood pressure independent of fibrinolytic response in Black but not White postmenopausal females
Marôco, João Luís , Szymanski, Linda M. , Baynard, Tracy , Fernhall, Bo, Marôco, João L , Fernhall, Bo

American Journal of Physiology-Heart and Circulatory Physiology | February 9, 2024 | Volume: 326 | Issue: 4 | Pages: H1053-H1059

10.1152/ajpheart.00023.2024 | PMID 38334975 Get It

Exaggerated SBP responses to exercise testing are more frequent in Black than in White male adults. Such responses, if translatable to females, may detect early racial disparities arriving during menopause. Because the endothelium regulates BP and fibrinolytic responses, these could be linked during exercise. At peak exercise, Black but not White postmenopausal females had more exaggerated SPB responses regardless of reduced fibrinolytic potential. Maximal exercise unmasked risk factors for cardiovascular disease in Black postmenopausal females.
Disease-Specific Mortality of Dermatofibrosarcoma Protuberans After Mohs Surgery Versus Wide Local Excision: A Systematic Review and Meta-Analysis
Demer, Addison M. , Brewer, Jerry D., Crum, Olivia M. , O'Hern, Keegan , O’Hern, Keegan

Dermatologic Surgery | February 9, 2024 | Volume: 50 | Issue: 4 | Pages: 317-321

10.1097/dss.0000000000004088 | PMID 38335454 Get It

BACKGROUND Although advances have been made in the understanding of recurrence patterns in dermatofibrosarcoma protuberans, the current understanding of disease-specific mortality after surgical management is limited. OBJECTIVE To understand disease-specific mortality rates associated with dermatofibrosarcoma protuberans treated with wide local excision (WLE) versus Mohs micrographic surgery (MMS). MATERIALS AND METHODS A systematic literature search was conducted on March 6, 2023, to identify patients treated with MMS or WLE for dermatofibrosarcoma protuberans. RESULTS A total of 136 studies met inclusion criteria. Overall, the disease-specific mortality rate was not significantly different after treatment with MMS (0.7%, confidence interval [CI] 0.1–1.2, p: 0.016) versus WLE (0.9%, CI 0.6–1.2, p < .001). For recurrent tumors, the MMS treatment group had a statistically significantly lower disease-specific mortality rate (1.0%, CI 0.0–2.0, p 0.046) compared with the WLE treatment group (3.5%, CI 2.0–5.1, p < .001). The mean follow-up for all studies was 57.6 months. CONCLUSION AND RELEVANCE The authors' meta-analysis suggests there is no substantial difference in disease-specific mortality between MMS and WLE in patients with dermatofibrosarcoma protuberans, except in the case of recurrent tumors, where MMS seems to confer a survival advantage.
Preoperative Anemia and Postoperative Outcomes in Cardiac Surgery: A Mediation Analysis Evaluating Intraoperative Transfusion Exposures
Hanson, Andrew C. , Schulte, Phillip J. , Sanz, Juan Ripoll, Kauss, Marissa L., Kor, Daryl J. , Warner, Matthew A. , Sanz, Juan G. Ripoll, Smith, Mark M. , Kauss, Marissa L. , Crestanello, Juan A.

Anesthesia & Analgesia | February 9, 2024 | Volume: 138 | Issue: 4 | Pages: 728-737

10.1213/ane.0000000000006765 | PMID 38335136 Get It

BACKGROUND: Preoperative anemia is associated with adverse outcomes in cardiac surgery, yet it remains unclear what proportion of this association is mediated through red blood cell (RBC) transfusions. METHODS: This is a historical observational cohort study of adults undergoing coronary artery bypass grafting or valve surgery on cardiopulmonary bypass at an academic medical center between May 1, 2008, and May 1, 2018. A mediation analysis framework was used to evaluate the associations between preoperative anemia and postoperative outcomes, including a primary outcome of acute kidney injury (AKI). Intraoperative RBC transfusions were evaluated as mediators of preoperative anemia and outcome relationships. The estimated total effect, average direct effect of preoperative anemia, and percent of the total effect mediated through transfusions are presented with 95% confidence intervals and P -values. RESULTS: A total of 4117 patients were included, including 1234 (30%) with preoperative anemia. Overall, 437 of 4117 (11%) patients went on to develop AKI, with a greater proportion of patients having preoperative anemia (219 of 1234 [18%] vs 218 of 2883 [8%]). In multivariable analyses, the presence of preoperative anemia was associated with increased postoperative AKI (6.4% [4.2%–8.7%] absolute difference in percent with AKI, P < .001), with incremental decreases in preoperative hemoglobin concentrations displaying greater AKI risk (eg, 11.9% [6.9%–17.5%] absolute increase in probability of AKI for preoperative hemoglobin of 9 g/dL compared to a reference of 14 g/dL, P < .001). The association between preoperative anemia and postoperative AKI was primarily due to direct effects of preoperative anemia (5.9% [3.6%–8.3%] absolute difference, P < .001) rather than mediated through intraoperative RBC transfusions (7.5% [−4.3% to 21.1%] of the total effect mediated by transfusions, P = .220). Preoperative anemia was also associated with longer hospital durations (1.07 [1.05–1.10] ratio of geometric mean length of stay, P < .001). Of this total effect, 38% (22%, 62%; P < .001) was estimated to be mediated through subsequent intraoperative RBC transfusion. Preoperative anemia was not associated with reoperation or vascular complications. CONCLUSIONS: Preoperative anemia was associated with higher odds of AKI and longer hospitalizations in cardiac surgery. The attributable effects of anemia and transfusion on postoperative complications are likely to differ across outcomes. Future studies are necessary to further evaluate mechanisms of anemia-associated postoperative organ injury and treatment strategies.
Developing a Risk Prediction Model for COVID-19 Infection in Heart Transplant Recipients Using Artificial Intelligence
Sharma, Shriya , Menon, N. Gayathri , Luce, Caitlyn, Brumble, Lisa , Bhattacharya, Anirban , Goswami, Rohan , Goswami, Rohan M , Menon, Nora , Ruiz, Jose

Future Virology | February 9, 2024 | Volume: 18 | Issue: 18 | Pages: 1123-1136

10.2217/fvl-2023-0162 Get It

Validated Symptom Outcomes Following Septal Perforation Repair: Application of the NOSE‐Perf Scale
Taylor, Cullen M. , Bansberg, Stephen F. , Marino, Michael J. , Taylor, Cullen

The Laryngoscope | February 9, 2024 | Volume: 134 | Issue: 7 | Pages: 3067-3072

10.1002/lary.31329 | PMID 38334159 Get It

ObjectiveThe Nasal Obstruction Symptom Evaluation (NOSE)‐Perf scale was developed and validated to measure symptoms associated with nasal septal perforations. This study reports the application of the NOSE‐Perf scale to evaluate symptom change following septal perforation repair.MethodsPatients with NOSE‐Perf evaluations ≥6 months following attempted perforation closure from July 2018 to December 2021 utilizing bilateral nasal mucosal flaps with an interposition graft were eligible for study inclusion. Change in NOSE‐Perf scores were noted. Patient demographics, perforation size, and concurrent functional procedures were analyzed for impact on symptom outcomes.ResultsOne‐hundred and seventeen patients met the study criteria. Seventy‐nine (67.5%) of the patients were female and the mean (range) age at surgery was 47.3 (14–78) years. Repair failure was noted in 7 (6.0%) patients. Mean (SD) preoperative NOSE‐Perf score was 25.3 (95% CI, 23.5–27.1) and postoperative score was 7.9 (95% CI, 6.5–9.3). Minimal clinically important difference (MCID) was estimated and greater than 91% of patients had improvement above this threshold. Patient age, perforation size, or concurrent functional procedures did not impact outcomes. Postoperative scores at short (2–4 months), intermediate (5–8 months), and long‐term (≥9 months) time periods showed significant improvement (all p < 0.001) compared to preoperative NOSE‐Perf scores.ConclusionSignificant reduction in nasal symptoms as measured by the NOSE‐Perf scale is noted following bilateral mucosal flap repair. Although the nose does not completely normalize following repair, clinically important improvement was noted in at least 91% of patients. The NOSE‐Perf scale is positioned to play a role in the standardization of septal perforation evaluation and outcomes assessment.Level of Evidence4 Laryngoscope, 134:3067–3072, 2024
An Update on the Use of Artificial Intelligence in Cardiovascular Medicine
Rao, Shiavax J. , Iqbal, Shaikh B. , Wang, Zhen , Glicksberg, Benjamin S. , Krittanawong, Chayakrit , Glicksberg, Benjamin , Isath, Ameesh , Virk, Hafeez Ul Hassan

Hearts | February 9, 2024 | Volume: 5 | Issue: 1 | Pages: 91-104

10.3390/hearts5010007 Get It

Artificial intelligence, specifically advanced language models such as ChatGPT, have the potential to revolutionize various aspects of healthcare, medical education, and research. In this review, we evaluate the myriad applications of artificial intelligence in diverse healthcare domains. We discuss its potential role in clinical decision-making, exploring how it can assist physicians by providing rapid, data-driven insights for diagnosis and treatment. We review the benefits of artificial intelligence such as ChatGPT in personalized patient care, particularly in geriatric care, medication management, weight loss and nutrition, and physical activity guidance. We further delve into its potential to enhance medical research, through the analysis of large datasets, and the development of novel methodologies. In the realm of medical education, we investigate the utility of artificial intelligence as an information retrieval tool and personalized learning resource for medical students and professionals.
Expert endoscopist assessment of colorectal polyp size using virtual scale endoscopy, visual or snare-based estimation: a prospective video-based study
Crainic, Ioana Popescu, Rex, Douglas K. , Hassan, Cesare , Pohl, Heiko , Rastogi, Amit, Anderson, Joseph C. , Taghiakbari, Mahsa , Medawar, Edgard , Renteln, Daniel von , East, James, Hassan, Cesare , Djinbachian, Roupen , Barkun, Alan , Shaukat, Aasma , East, James E. , Mori, Yuichi , Sharma, Prateek

Scandinavian Journal of Gastroenterology | February 9, 2024 | Volume: 59 | Issue: 5 | Pages: 608-614

10.1080/00365521.2024.2308519 | PMID 38333956 Get It

Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview
Mercado, Lydia A., Gil-López, F. Santoyo, Chirilă, Răzvan M. , Harnois, Denise M. , Gil-López, Fernando

Diagnostics | February 9, 2024 | Volume: 14 | Issue: 4 | Pages: 382

10.3390/diagnostics14040382 | PMID 38396421 Get It

Autoimmune hepatitis is an immune-mediated inflammatory condition of the liver of undetermined cause that affects both sexes, all ages, races, and ethnicities. Its clinical presentation can be very broad, from having an asymptomatic and silent course to presenting as acute hepatitis, cirrhosis, and acute liver failure potentially requiring liver transplantation. The diagnosis is based on histological abnormalities (interface hepatitis), characteristic clinical and laboratory findings (increased aspartate aminotransferase, alanine aminotransferase, and serum IgG concentration), and the presence of one or more characteristic autoantibodies. The large heterogeneity of these clinical, biochemical, and histological findings can sometimes make a timely and proper diagnosis a difficult task. Treatment seeks to achieve remission of the disease and prevent further progression of liver disease. First-line therapy includes high-dose corticosteroids, which are later tapered to decrease side effects, and azathioprine. In the presence of azathioprine intolerance or a poor response to the standard of care, second-line therapy needs to be considered, including mycophenolate mofetil. AIH remains a diagnostic and therapeutic challenge, and a further understanding of the pathophysiological pathways of the disease and the implementation of randomized controlled trials are needed.
New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors
Gangat, Naseema , Tefferi, Ayalew

American Journal of Hematology | February 9, 2024 | Volume: 99 | Issue: 5 | Pages: 978-981

10.1002/ajh.27248 | PMID 38332640 Get It